Baudax Bio Receives FDA Orphan Drug Designation For TI-168 For Hemophilia A With Inhibitors
Portfolio Pulse from Benzinga Newsdesk
Baudax Bio has received FDA Orphan Drug Designation for TI-168, a drug aimed at treating Hemophilia A with inhibitors. This designation could provide various benefits including tax credits, market exclusivity, and FDA assistance in clinical trial design.
September 28, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baudax Bio's stock could potentially see a positive impact due to the FDA Orphan Drug Designation for TI-168. This designation could lead to market exclusivity and other benefits for the company.
The FDA Orphan Drug Designation is a significant milestone for pharmaceutical companies. It provides various benefits including tax credits, market exclusivity, and FDA assistance in clinical trial design. This could potentially lead to increased revenues for Baudax Bio, positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100